This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.This is an 18-month study looking at prevention of coronary artery disease progression in people with impaired glucose tolerance on rosiglitazone vs. placebo.
Showing the most recent 10 out of 1065 publications